Data Insights
                                    By  Company Name
                                
                                No Filter Selected
                                    By  Disease Name
                                
                                No Filter Selected
                                    By  Drug Name
                                
                                No Filter Selected
                                    By Themes
                                
                                No Filter Selected
                                    Showing 2 results out of 2                                
                                
                                                Data Insights
                                                
                                        HB-adMSC Allogeneic by Hope Biosciences for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
HB-adMSC Allogeneic is under clinical development by Hope Biosciences and currently in Phase II for Post-Acute Sequelae of COVID 2019...
                                                Data Insights
                                                
                                        HB-adMSC Allogeneic by Hope Biosciences for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
HB-adMSC Allogeneic is under clinical development by Hope Biosciences and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According...
